Update on biologics in juvenile idiopathic arthritis

Norman T. Ilowite

Research output: Contribution to journalReview article

40 Scopus citations

Abstract

As experience is gained, and longer-term safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the course of patients who inadequately respond to conventional disease-modifying antirheumatic drugs.

Original languageEnglish (US)
Pages (from-to)613-618
Number of pages6
JournalCurrent opinion in rheumatology
Volume20
Issue number5
DOIs
StatePublished - Sep 1 2008

    Fingerprint

Keywords

  • Interleukin-1
  • Interleukin-6
  • Juvenile idiopathic arthritis
  • Tumor necrosis tor
  • Uveitis

ASJC Scopus subject areas

  • Rheumatology

Cite this